Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Cash & Equivalents (2016 - 2025)

Orthofix Medical (OFIX) has disclosed Cash & Equivalents for 16 consecutive years, with $82.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 1.46% year-over-year to $82.0 million, compared with a TTM value of $82.0 million through Dec 2025, down 1.46%, and an annual FY2025 reading of $82.0 million, down 1.46% over the prior year.
  • Cash & Equivalents was $82.0 million for Q4 2025 at Orthofix Medical, up from $62.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $94.6 million in Q1 2021 and bottomed at $26.4 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $58.4 million, with a median of $58.7 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents plummeted 53.75% in 2021, then surged 151.42% in 2024.
  • Year by year, Cash & Equivalents stood at $87.8 million in 2021, then tumbled by 42.29% to $50.7 million in 2022, then tumbled by 34.7% to $33.1 million in 2023, then soared by 151.42% to $83.2 million in 2024, then decreased by 1.46% to $82.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for OFIX at $82.0 million in Q4 2025, $62.9 million in Q3 2025, and $65.6 million in Q2 2025.